secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2026-06-11T11:16:14+00:00
Accession:  0001867096-26-000045
Event type: debt
Sentiment:  positive
Materiality: 0.70
Item codes: 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris Biopharma exchanges ~69% of 8% Convertible Notes due 2028 for cash and stock
--------------------------------------------------------------------------------

- Entered private exchange to retire ~$23M (69%) of 8% Convertible Senior Notes due 2028.
- Exchange consideration: $23M cash plus shares based on 21-day VWAP; ~4.6M shares if price is $6.71.
- After exchange, $10.5M notes remain outstanding; annual interest savings ~$2M.
- Expected close around July 15, 2026; Morgan Stanley acted as placement agent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709626000045/0001867096-26-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709626000045/xers-20260610.htm
  HTML page:      https://secwatch.observer/filing/0001867096-26-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer